Headache News and Research

Latest Headache News and Research

Study offers a very hopeful message for individuals struggling with migraines

A new study from researchers at the University of Toronto found that 63% of Canadians with migraine headaches are able to flourish, despite the painful condition.

24 Jun 2021

Long COVID has low prevalence in school-age children, UK study suggests

A new study, released as a preprint on the medRxiv* server, offers some insights into what may be expected in this field, how common it is, how it presents, and how it compares with chronic sequelae of other respiratory viruses.

24 Jun 2021

Vaccine side effects should be viewed as a sign of efficacy, say immunologists

The rapid development of safe and efficacious vaccines against SARS-CoV-2 has offered hope that the global COVID-19 pandemic may soon be under control. However, vaccinations remain incomplete in many developed nations, and lag further still in the developing world.

23 Jun 2021

Benefits of COVID-19 vaccination outweigh the complications, long-term effects of the disease

An international study, headed by Antonio Hernández, Professor of the Department of Legal Medicine, Toxicology and Physical Anthropology of the University of Granada, has reviewed the assessment reports of the European Medicines Agency regarding the Coronavirus vaccines produced by Pfizer, Moderna, and AstraZeneca.

21 Jun 2021

New consensus statement on sport-related concussion aims to help doctors provide optimal medical care

Strict rest after a sports related concussion slows recovery and may prolong symptoms, says a consensus statement drawn up by a US expert panel on how best to treat and manage the condition, and published in the British Journal of Sports Medicine.

17 Jun 2021

New web tool offers many capabilities vital to bacteria mutation research

In 1943, two scientists named Max Delbrück and Salvador Luria conducted an experiment to show that bacteria can mutate randomly, independent of external stimulus, such as an antibiotic that threatens a bacterial cells' survival.

15 Jun 2021

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Healthcare professionals and public health authorities have a central role in discussing vaccination against COVID-19 with their patients.

13 Jun 2021

Study: COVID-19 vaccines safe for IBD patients

Patients with inflammatory bowel diseases (IBD) do not appear to have increased risk of side effects from the Pfizer or Moderna COVID-19 vaccines, according to a recent Cedars-Sinai study published online and upcoming in print in the American Journal of Gastroenterology.

9 Jun 2021

Are women more likely to develop long COVID?

Researchers found different groups of symptoms persisting after coronavirus disease 2019 (COVID-19), with fatigue and higher IL-6 levels common in women. About 75% of the patients they treated were women, indicating a link between sex hormones and immune response.

8 Jun 2021

Study reports safety, efficacy of targeted treatment for IgA nephropathy

IgA nephropathy (IgAN) is a chronic kidney disease occurring in young adults and is one of the most common reasons for kidney transplantation in this age group.

7 Jun 2021

FDA grants accelerated approval for first-of-its-kind Alzheimer's treatment

Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer's, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

7 Jun 2021

Around 5% of children develop long COVID-19 symptoms, suggests new study

A new study, by researchers at University College London (UCL) in the UK, shows that even though children rarely develop symptomatically severe COVID-19, the prevalence of long COVID in children with a history of infection is over 4.5%.

7 Jun 2021

Could sustained inflammation following mild to moderate COVID-19 be a driver of long COVID?

A new study describes the discovery of sustained though low-level rises in inflammatory mediators and immune cells, as well as the loss of some subsets of naïve un-activated cells. This may indicate a widespread though muted immune-mediated inflammatory response in these patients.

7 Jun 2021

FDA approves new treatment for patients with hypoplasminogenemia

Today, the U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a disorder that can impair normal tissue and organ function and may lead to blindness.

5 Jun 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021

Mental health effects common among mild and severe cases of COVID-19

Findings on mental health outcomes of COVID-19 infection show frequent symptoms associated with lasting neurological symptoms.

4 Jun 2021

Three cases of stroke reported in young adults following covid-19 vaccination

Clots in the arteries (arterial thrombosis) are the most common cause of stroke (ischemic stroke) and have been reported in detail for the first time in young adults who received the Oxford–AstraZeneca covid-19 vaccine in a letter from UK stroke specialists published online in Journal of Neurology Neurosurgery & Psychiatry.

4 Jun 2021

Could certain genes be associated with a loss of smell in some COVID-19 patients?

Researchers at the 23andMe COVID-19 Team, who help search for genetic links associated with the severity of COVID-19, found that the genes UGT2A1 and UGT2A2 may be associated with the loss of smell in those infected with SARS-CoV-2.

2 Jun 2021

NIH launches first-in-human, Phase 1 trial assessing investigational nanoparticle influenza vaccine

A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.

1 Jun 2021

Unique observational tool developed for assessing children with concussion

A research team led by scientists at Université de Montréal has developed a unique observational tool for assessing children up to 5 years of age who have had a concussion.

1 Jun 2021